Camille G. Wermuth

Last updated

Camille Georges Wermuth (died September 2015) [1] was a chemist in the Laboratoire de Pharmacochimie Moleculaire at the Universite Louis Pasteur in Illkirch, France. He is particularly known for his editing of The Practice of Medicinal Chemistry (1996) which has been issued in four editions.

Selected publications

Related Research Articles

In chemistry, a hydrochloride is an acid salt resulting, or regarded as resulting, from the reaction of hydrochloric acid with an organic base. An alternative name is chlorhydrate, which comes from French. An archaic alternative name is muriate, derived from hydrochloric acid's ancient name: muriatic acid.

<span class="mw-page-title-main">Medicinal chemistry</span> Scientific branch of chemistry

Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacy involved with designing and developing pharmaceutical drugs. Medicinal chemistry involves the identification, synthesis and development of new chemical entities suitable for therapeutic use. It also includes the study of existing drugs, their biological properties, and their quantitative structure-activity relationships (QSAR).

A prodrug is a pharmacologically inactive medication or compound that, after intake, is metabolized into a pharmacologically active drug. Instead of administering a drug directly, a corresponding prodrug can be used to improve how the drug is absorbed, distributed, metabolized, and excreted (ADME).

<span class="mw-page-title-main">Pharmacophore</span> Abstract description of molecular features

In medicinal chemistry and molecular biology, a pharmacophore is an abstract description of molecular features that are necessary for molecular recognition of a ligand by a biological macromolecule. IUPAC defines a pharmacophore to be "an ensemble of steric and electronic features that is necessary to ensure the optimal supramolecular interactions with a specific biological target and to trigger its biological response". A pharmacophore model explains how structurally diverse ligands can bind to a common receptor site. Furthermore, pharmacophore models can be used to identify through de novo design or virtual screening novel ligands that will bind to the same receptor.

<span class="mw-page-title-main">Orphenadrine</span> Severe pain, and for low back pain, acute setting is preferred

Orphenadrine is an anticholinergic drug of the ethanolamine antihistamine class; it is closely related to diphenhydramine. It is a muscle relaxant that is used to treat muscle pain and to help with motor control in Parkinson's disease, but has largely been superseded by newer drugs. It is considered a dirty drug due to its multiple mechanisms of action in different pathways. It was discovered and developed in the 1940s.

<span class="mw-page-title-main">Norethandrolone</span> Chemical compound

Norethandrolone, sold under the brand names Nilevar and Pronabol among others, is an androgen and anabolic steroid (AAS) medication which has been used to promote muscle growth and to treat severe burns, physical trauma, and aplastic anemia but has mostly been discontinued. It is still available for use in France however. It is taken by mouth.

The Carr index is an indicator of the compressibility of a powder. It is named after the scientist Ralph J. Carr, Jr.

<span class="mw-page-title-main">Minaprine</span> Chemical compound

Minaprine is a monoamine oxidase inhibitor antidepressant drug that was used in France for the treatment of depression until it was withdrawn from the market in 1996 because it caused convulsions.

<span class="mw-page-title-main">T-HCA</span> Chemical compound

trans-4-Hydroxycrotonic acid (T-HCA), also known as γ-hydroxycrotonic acid (GHC), is an agent used in scientific research to study the GHB receptor. It is an analogue of γ-hydroxybutyric acid (GHB), as well as an active metabolite of GHB. Similarly to GHB, T-HCA has been found to be endogenous to the rat central nervous system, and as a metabolite of GHB, is almost certain to be endogenous to humans as well. T-HCA binds to the high-affinity GHB receptor with 4-fold greater affinity than GHB itself, where it acts as an agonist, but does not bind to the low-affinity GHB binding site, the GABAB receptor. Because of this, T-HCA does not produce sedation. T-HCA has been shown to cause receptor activation-evoked increases in extracellular glutamate concentrations, notably in the hippocampus.

<span class="mw-page-title-main">LY-307,452</span> Chemical compound

LY-307,452 is a drug used in neuroscience research, which was among the first compounds found that acts as a selective antagonist for the group II metabotropic glutamate receptors (mGluR2/3), and was useful in early studies of this receptor family, although it has largely been replaced by newer drugs such as LY-341,495. Its molecular formula is C21H25NO4

<span class="mw-page-title-main">Penmesterol</span> Chemical compound

Penmesterol, or penmestrol, also known as 17α-methyltestosterone 3-cyclopentyl enol ether, is a synthetic, orally active anabolic-androgenic steroid (AAS) that was developed in the early 1960s. It is the 3-cyclopentyl enol ether of methyltestosterone.

<span class="mw-page-title-main">Progestogen ester</span> Drug class

A progestogen ester is an ester of a progestogen or progestin. The prototypical progestogen is progesterone, an endogenous sex hormone. Esterification is frequently employed to improve the pharmacokinetics of steroids, including oral bioavailability, lipophilicity, and elimination half-life. In addition, with intramuscular injection, steroid esters are often absorbed more slowly into the body, allowing for less frequent administration. Many steroid esters function as prodrugs.

<span class="mw-page-title-main">Pentagestrone</span> Chemical compound

Pentagestrone, also known as 17α-hydroxyprogesterone 3-cyclopentyl enol ether, is a steroidal progestin of the 17α-hydroxyprogesterone group that was never marketed. An acetate ester, pentagestrone acetate, has been marketed for clinical use. Pentagestrone was described in the literature in 1960.

<span class="mw-page-title-main">Pentagestrone acetate</span> Chemical compound

Pentagestrone acetate (PGA), sold under the brand names Gestovis and Gestovister, is a progestin which was described in the literature in 1960 and was introduced by Vister in Italy in 1961. It is the 3-cyclopentyl enol ether of 17α-hydroxyprogesterone acetate. PGA, along with quingestrone, is said to have very similar properties to those of dydrogesterone, a pure progestogen and close analogue of progesterone.

<span class="mw-page-title-main">Bisdehydrodoisynolic acid</span> Chemical compound

Bisdehydrodoisynolic acid (BDDA), as the (Z)-isomer ( -BDDA), is a synthetic, nonsteroidal estrogen related to doisynolic acid that was never marketed. It is one of the most potent estrogens known, although it has more recently been characterized as a selective estrogen receptor modulator (SERM). BDDA and other doisynolic acid derivatives display relatively low affinity accompanied by disproportionately high estrogenic potency in vivo, which was eventually determined to be due to transformation into metabolites with greater estrogenic activity. The drug was discovered in 1947 as a degradation product of the reaction of equilenin or dihydroequilenin with potassium hydroxide. It is the seco-analogue of equilenin, while doisynolic acid is the seco-analogue of estrone. These compounds, along with diethylstilbestrol, can be considered to be open-ring analogues of estradiol. The methyl ether of BDDA, doisynoestrol, is also an estrogen, and in contrast to BDDA, has been marketed.

<span class="mw-page-title-main">Allenestrol</span> Chemical compound

Allenestrol, or allenoestrol, also known as α,α-dimethyl-β-ethylallenolic acid or as methallenestrilphenol, is a synthetic, nonsteroidal estrogen and a derivative of allenolic acid that was never marketed. A methyl ether of allenestrol, methallenestril (methallenestrol), is also an estrogen, but, in contrast to allenestrol, has been marketed.

<span class="mw-page-title-main">Estradiol benzoate cyclooctenyl ether</span> Chemical compound

Estradiol benzoate cyclooctenyl ether (EBCO), or estradiol 3-benzoate 17β-cyclooctenyl ether, is a synthetic estrogen as well as estrogen ester and ether – specifically, the C3 benzoate ester and C17β cyclooctenyl ether of estradiol – which was described in the early 1970s and was never marketed. It has been found to have a dramatically prolonged duration of action with oral administration in animals, similarly to the related compound quinestrol. A single oral dose of EBCO sustained high uterus weights for 3 weeks in rats. This long-lasting activity may be due to storage of EBCO in fat. It appears that EBCO is absorbed satisfactorily from the gastrointestinal tract, at least partially survives first-pass metabolism in the liver and intestines, and is then sequestered into fat, from which it is slowly released and activated into estradiol. In contrast to quinestrol, the oral activity of EBCO is greatly improved when it is delivered in an oil solution as opposed to an aqueous vehicle.

Jean-François Borel is a Belgian microbiologist and immunologist who is considered one of the discoverers of cyclosporin.

Alexandros Makriyannis is an American biochemist and professor of chemistry and chemical biology in the department of medicinal chemistry at Northeastern University in Boston, Massachusetts, where he directs the Center for Drug Discovery and holds the George Behrakis Chair of Pharmaceutical Biotechnology. His research has focused on the biochemical basis of the endocannabinoid system and on the development of synthetic cannabinoids.

References

  1. "In Memoriam: Camille Georges Wermuth". Chemistry International . 38 (1). 1 January 2016. doi: 10.1515/ci-2016-0116 .
  2. Camille Georges Wermuth, ed. (2008). The Practice of Medicinal Chemistry (Third ed.). ISBN   978-0-12-374194-3.